AFP and hepatocellular carcinoma: Palliative treatment prior to DAA treatment (hazard ratio (HR) = 3.974, 95% confidence interval (CI) 1.924–8.207, p = 0.0006), and AFP at SVR12 (HR = 1.048, 95% CI 1.016–1.077, p = 0.0047) were found to be significant risk factors contributing to HCC-R after DAA treatment (Table 3).